On February 20, 2026, the FDA sent warning letters to 30 telehealth companies. The charge: false or misleading claims about compounded GLP-1 drugs, and what the agency characterized as illegal marketing of weight-loss medications.

The primary violations were specific. Companies were implying that their compounded semaglutide or tirzepatide was equivalent to FDA-approved products like Ozempic, Wegovy, and Zepbound. Some obscured the sourcing of their active pharmaceutical ingredients. Others failed to disclose risks with the balance required by federal drug advertising law.

The enforcement is part of a pattern that goes back to February 6, when FDA Commissioner Makary publicly announced an upcoming crackdown on GLP-1 claims and importation. The February 20 letters represented a first wave; a second round followed in early March, extending the sweep further into the telehealth sector.

What sits beneath the enforcement action is a genuine tension in the market. Brand-name GLP-1 drugs remain expensive and coverage-dependent. Compounded alternatives filled the gap when Ozempic and Wegovy were on shortage lists. As manufacturers restored supply and FDA moved to remove compounded versions from its shortage exemptions, the telehealth companies that built business models around that gap found themselves in the agency's crosshairs.

Patients who accessed care through these channels deserve accurate information. That is the clinical principle behind the warning letters. Whether enforcement removes bad actors or simply removes access is the question that follows.

-- NORA WHITFIELD, Washington